Bharat biotech limited, Biotechnology company

Indigenous COVID-19 vaccine maker Bharat Biotech on Tuesday said the supply price of Covaxin to the Government of India at Rs 150 per dose is a non-competitive price and not sustainable in the long run, hence a higher price in private markets is required to offset part of the costs."The supply price of Covaxin to the government of India at Rs 150 per dose, is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs," Bharat Biotech said in a statement.The company said, as directed by the Government of India, less than 10 per cent of the total production of Covaxin to date has been supplied to private hospitals, while most of the remaining quantity was supplied to state and central government."As directed by the Government of India, less than 10 per cent of our total production of Covaxin to date has been supplied to private hospitals, while most of the remaining quantity was supplied to state and central governments. In such a scenario the weighted average price of covaxin for all supplies realized by Bharat Biotech is less than Rs 250 per dose. Going forward, ~75 per cent of the capacity will be supplied to state and central governments with only 25 per cent going to private hospitals," the statement read.The company clarifies that the procurement of vaccines by private hospitals is optional and not mandatory, albeit it gives a choice to citizens who are willing to pay for better convenience."Unlike most medicines and therapeutics, vaccines are provided free of cost by the Government of India to all eligible Indian citizens. Thus, the procurement of vaccines by private hospitals is optional and not mandatory, albeit it gives a choice to citizens who are willing to pay for better convenience. In our view, the question of product pricing is only of extraneous interest to all concerned, especially when the same vaccine is made available free of cost," it said.Hyderabad-based vaccine manufacturer also added that it is pertinent to mention the urgent need to set up a significant number of manufacturing facilities and to divert existing ones for Covaxin, which has resulted in reduced production of other vaccines at our facilities, leading to a loss in revenues."Product development activities towards the development of vaccines against newer variants are also underway at our facilities," the statement revealed.Bharat Biotech mentioned that it should be allowed to maintain a differential pricing strategy for governments and private hospitals."It should be noted that companies such as Bharat Biotech, which are innovators with specialized expertise in product development, and large scale manufacturing, should be allowed to maintain a differential pricing strategy for governments and private hospitals," said the company statement.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Bharat Biotech LimitedFOLLOW

Bharat biotech limited, Latest News

The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said. ...

The Subject Expert Committee (SEC) under the drug regulator will discuss reviewing the Phase III data of Bharat Biotech's Covaxin on Tuesday. ...

The Hyderabad-based COVID vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to Drugs Controller General of India (DCGI) over the weekend, according to government sources. ...

Hyderabad-based Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use Listing (EUL) of its indigenous COVID-19 vaccine Covaxin. ...

India will bounce back after the major devastation it suffered during the second wave of the Covid-pandemic and the crisis cannot deter the "rise of the great country as a global super power," Shin Bong-Kil, the South Korean envoy to India said on We ...

The Union Health Ministry on Wednesday said that newborn calf serum is not an ingredient of the final Covaxin vaccine by Bharat Biotech. ...

Hyderabad, June 16 Bharat Biotech on Wednesday clarified that while new born calf serum is used in the ... ...

Indigenous COVID-19 vaccine maker Bharat Biotech on Tuesday said the supply price of Covaxin to the Government of India at Rs 150 per dose is a non-competitive price and not sustainable in the long run, hence a higher price in private markets is requ ...